Haemophilus Influenzae Type Infection
📧 Sign up to get email alerts when something new happens for Haemophilus Influenzae Type Infection.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-02-18Clinical Trial Update: Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea
This is a completed post-marketing surveillance study assessing the safety of the DTaP-IPV-HB-PRP-T vaccine in Korea.
-
CLINICAL_TRIALS research · 2025-12-31Clinical Trial Update: Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine [Phase 1]
This is a Phase 1 clinical trial evaluating an adsorbed, acellular pertussis vaccine component combined with Hib and ACWY meningococcal comp…
-
CLINICAL_TRIALS trial_result · 2025-09-22Clinical Trial Update: Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand [Phase 3]
Phase 3 study evaluating the DTwP-HepB-Hib-IPV (SHAN6) vaccine administered with routine vaccines in healthy infants and toddlers in Thailan…
-
CLINICAL_TRIALS trial_result · 2025-07-29Clinical Trial Update: Clinical Trial of Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine [Phase 1]
The entry reports a Phase 1 clinical trial for a lyophilized Haemophilus influenzae type b conjugate vaccine by CanSino Biologics, currently…
-
CLINICAL_TRIALS research · 2024-11-15Clinical Trial Update: Phase I/II, Open Label, Randomized, Safety and Immunogenicity Following DTwP-Hepatitis B-Hib-IPV Vaccine (Bio Farma) in Indonesian Infants [Phase 1, Phase 2]
Clinical trial update on a Phase 1/2 safety and immunogenicity study of a pentavalent DTwP-HepB-Hib-IPV vaccine in Indonesian infants; the t…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-10-01Clinical Trial Update: Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age [Phase 2]
Phase 2 trial to evaluate the immunogenicity of LR20062 versus control in healthy infants at 2, 4, and 6 months of age. The study targets pr…
-
CLINICAL_TRIALS research · 2024-09-20Clinical Trial Update: Safety and Immunogenicity of DTaP-IPV/Hib Pentavalent Vaccine in Chinese 2-month-old Infants [NA]
This clinical trial is evaluating the safety and immunogenicity of a pentavalent DTaP-IPV/Hib vaccine in 2-month-old Chinese infants; the st…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Exploratory Clinical Study of MT-2301 [Phase 2]
MT-2301 completed a Phase 2 exploratory study for Haemophilus influenzae type b infections; results were posted in September 2024.
-
CLINICAL_TRIALS research · 2024-09-19Clinical Trial Update: Clinical Study to Assess the Immunogenicity and Safety of Hexavalent Vaccine Containing Reduced Dose IPV [Phase 3]
This document reports a Phase 3 clinical trial evaluating the immunogenicity and safety of a hexavalent vaccine that contains a reduced-dose…
-
CLINICAL_TRIALS trial_result · 2024-06-24Clinical Trial Update: Immunogenicity of H. Influenzae Type b PRP-OMP Vaccines in American Indian and Alaska Native Children (the HibVax Study) [Phase 4]
Phase 4 trial update assessing the immunogenicity of Haemophilus influenzae type B PRP-OMP vaccines in American Indian and Alaska Native chi…
-
CLINICAL_TRIALS trial_result · 2023-09-06Clinical Trial Update: Safety, Tolerability, and Immunogenicity of Vaxelis™ in Children Previously Vaccinated With Vaxelis™ or Hexyon™ (V419-016) [Phase 4]
Phase 4 study assessing safety, tolerability, and immunogenicity of the hexavalent vaccine Vaxelis in children previously vaccinated with Va…
-
CLINICAL_TRIALS trial_result · 2023-03-10Clinical Trial Update: Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series [Phase 2, Phase 3]
Phase 2/3 clinical trial evaluating the immunogenicity and safety of LBVD(Hexavalent Vaccine) in healthy infants as part of the primary seri…
-
CLINICAL_TRIALS trial_result · 2019-09-06Clinical Trial Update: Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants [Phase 2]
Phase 2 study assessing safety and immunogenicity of a hexavalent DTwP-HepB-IPV-Hib vaccine in healthy infants; status not specified.
-
CLINICAL_TRIALS trial_result · 2019-08-14Clinical Trial Update: A Phase IV Study to Assess the Safety of EupentaTM Inj [Phase 4]
Phase IV study update assessing the safety of EupentaTM Inj; the document lists multiple conditions and an unknown status for the trial.
-
CLINICAL_TRIALS trial_result · 2019-07-19Clinical Trial Update: A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia [Phase 3]
Phase 3 trial assessing immunogenicity and safety of Infanrix-IPV/Hib given in a three-dose schedule with a booster in healthy infants in Ru…
-
CLINICAL_TRIALS research · 2017-11-17Clinical Trial Update: Mobile Phone SMS Messages and Automated Calls in Improving Vaccine Coverage Among Children in Pakistan [NA]
This clinical trial update from Aga Khan University evaluates whether mobile phone SMS messages and automated calls can improve vaccine cove…
-
CLINICAL_TRIALS trial_result · 2017-08-18Clinical Trial Update: Non-inferiority of GSK Biologicals' DTPw-HBV/Hib Compared to Two Formulations of GSK Biologicals' DTPw-HBV/Hib [Phase 3]
Phase 3 trial shows non-inferiority of GSK's DTPw-HBV/Hib vaccine compared to two alternative formulations.
-
CLINICAL_TRIALS trial_result · 2017-06-26Clinical Trial Update: Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine [Phase 2]
Phase 2 trial evaluating the immunogenicity and safety (reactogenicity) of a booster dose of GSK's DTPa-HBV-IPV/Hib vaccine, with results po…
-
CLINICAL_TRIALS trial_result · 2017-06-16Clinical Trial Update: Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered Separately [Phase 3]
Phase 3 trial compares the immunogenicity and reactogenicity of the hexavalent vaccine DTPa-HBV-IPV/Hib with the separate DTPa-HBV-IPV and H…
-
CLINICAL_TRIALS trial_result · 2017-06-16Clinical Trial Update: Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly [Phase 2]
Phase 2 study assessing immunogenicity and safety of DTPa-HBV-IPV/Hib versus DTPa-IPV/Hib with concomitant hepatitis B administration, compl…
-
CLINICAL_TRIALS trial_result · 2017-05-19Clinical Trial Update: Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent (DTwP-Hib-Hep B) Vaccine in Infants 6-8 Weeks of Age [Phase 3]
Phase 3 study evaluating immunogenicity, safety, and tolerability of a fully liquid pentavalent vaccine (DTwP-Hib-HepB) in infants aged 6-8 …
-
CLINICAL_TRIALS trial_result · 2017-04-26Clinical Trial Update: DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants [Phase 3]
Phase 3 trial comparing a DTaP-IPV-HepB-PRP-T vaccine with a DTaP-IPV-PRP-T vaccine plus Hep B in Hep B-primed infants has completed.
-
CLINICAL_TRIALS trial_result · 2017-04-13Clinical Trial Update: Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine [Phase 3]
A Phase 3 immunogenicity and safety study evaluating a booster dose of GSK's Poliorix (IPV) and Infanrix+Hib (DTPa/Hib) has completed with r…
-
CLINICAL_TRIALS trial_result · 2017-04-10Clinical Trial Update: Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine [Phase 3]
Phase 3 immunogenicity and safety study of GSK's Infanrix-IPV+Hib vaccine completed with results posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-04-04Clinical Trial Update: Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age. [Phase 2]
Phase 2 feasibility study of GSK's GSK2202083A vaccine in healthy infants at 3, 5, and 11 months was terminated, with results posted in 2017…